Autonomix Medical

Autonomix Medical Quick Ratio

The Quick Ratio (Acid Test) of Autonomix Medical (AMIX) as of Oct 20, 2026 is 4.45. In the previous year, Quick Ratio (Acid Test) was 3.51 — a change of 26.69% (higher).

Quick Ratio

4.45

YoY

26.69%

Last updated:

Quick Ratio (Acid Test) of Autonomix Medical is 2026 4.45 . Quick Ratio (Acid Test) of Autonomix Medical was 2025 3.51 . It decreases by 26.69% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autonomix Medical Stock analysis

What does Autonomix Medical do? Autonomix Medical Inc develops medical devices focused on treating peripheral nervous system diseases. The company's technology platform features a catheter-based microchip sensing array capable of detecting peripheral neural signals with up to 1,000 times sensitivity. It is developing a dual-function technology that both detects malfunctioning neural signals and ablates nerves in a single procedure for pain management. The company targets conditions like pancreatic cancer and pancreatitis, which cause severe pain requiring effective solutions. Its Autonomix catheter uses a microchip to convert body analog signals into digital signals for direct transmission to a computer. The company's products include the Autonomix catheter and its underlying technology platform. These are designed for medical professionals treating conditions involving the peripheral nervous system. The primary segments served are patients suffering from pancreatic cancer, pancreatitis, and other peripheral nervous system disorders requiring pain management solutions. The technology platform has potential applications across multiple medical fields including cardiology, renal denervation, and chronic pain management. Autonomix Medical Inc's revenue model is based on developing and commercializing its medical device technology. The company is focused on creating solutions for specific medical conditions where current treatments are inadequate. Its dual-function technology represents a novel approach to pain management by combining detection and ablation capabilities in one procedure. The company's target market includes healthcare providers seeking advanced solutions for peripheral nervous system diseases and chronic pain conditions. Autonomix Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autonomix Medical stock

Quick Ratio (Acid Test) of Autonomix Medical is 4.45 in 2026.

Quick Ratio (Acid Test) of Autonomix Medical changed from 3.51 to 4.45, representing a 26.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Autonomix Medical since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Autonomix Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Autonomix Medical

All Key Metrics — Autonomix Medical